Who Paid My Doc
Megan Elios
Pediatric Allergy/Immunology Chicago, IL Medical Doctor
NPI 1043690282 CMS profile 1340061
5841 S Maryland Ave # Mc5042, Chicago, IL 60637
General payments
$235
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Megan Elios of Chicago, IL is reported in the CMS Open Payments database as having received $235 across 7 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 22nd percentile of Pediatric Allergy/Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $114 | 1 | |
| 2020 | General | $70 | 3 | |
| 2019 | General | $51 | 3 |
Beside peers
- Megan Elios
- Pediatric Allergy/Immunology median
- Middle half of Pediatric Allergy/Immunology
- National median
In program year 2025, general payments to Megan Elios were reported at $114. Among 289 Pediatric Allergy/Immunology profiles paid that year, the median was $361 and the middle half received between $125 and $2,493.
Show as a table
| Year | Megan Elios | Pediatric Allergy/Immunology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $51 | $325 | $92–$1,399 | $163 |
| 2020 | $70 | $144 | $66–$2,490 | $114 |
| 2021 | $0 | $357 | $95–$2,633 | $132 |
| 2022 | $0 | $385 | $125–$2,259 | $149 |
| 2023 | $0 | $470 | $121–$2,946 | $160 |
| 2024 | $0 | $317 | $125–$2,583 | $164 |
| 2025 | $114 | $361 | $125–$2,493 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 3 drugsPart D claims
52
Drug cost
$904
Branded share of claims
38.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | Brand | 20 | $583 | |
| Azelastine Hcl | Generic | 17 | $266 | |
| Montelukast Sodium | Generic | 15 | $55 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.
Records
7 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Allergy/Immunology in Illinois
Jennifer Kim
Pediatric Allergy/Immunology · Glenview, IL
James Moy
Pediatric Allergy/Immunology · Chicago, IL
Steve Handoyo
Pediatric Allergy/Immunology · Chicago, IL
Abigail Lang
Pediatric Allergy/Immunology · Chicago, IL
Michael Sherenian
Pediatric Allergy/Immunology · Chicago, IL
Tori Ly
Pediatric Allergy/Immunology · Chicago, IL
Related records
Pediatric Allergy/Immunology in Illinois
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Allergy/Immunology
Everyone recorded under this specialty, nationwide.
Doctors in Illinois
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.